DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Ma X, Lalezari J, Nguyen T. , et al.
Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients.
J Hepatol 2019;
70: e130-e131
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.